Study of DISC-3405 for people with sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have sickle cell disease type HbSC or HbSS.
- You have had between 1 and 10 pain crises (VOC) in the past year, or have had other SCD complications like eye problems, silent stroke, bone issues, hearing loss, priapism, or organ problems.
- Your hemoglobin level is at least 7.0 g/dL (first two participants need at least 9.0 g/dL).
- You have not had a blood transfusion or phlebotomy in the last 60 days, and you are not on regular transfusion therapy.
- You are not currently hospitalized for a pain crisis or other SCD problem, and you have not had acute chest syndrome in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This trial tests a high-dose medicine to collect stem cells from young adults with sickle cell disease. It aims to prepare for a transplant that could potentially cure the condition.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.